Corrections:

Abhishek D. Garg¹, Sanne Elsen², Dmitri V. Krysko^3,4, Peter Vandenabeele^3,4, Peter de Witte² and Patrizia Agostinis¹

¹Cell Death Research & Therapy (CDRT) Unit, Department of Cellular and Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium
²Laboratory for Molecular Biodiscovery, Department of Pharmaceutical Sciences, KU Leuven, Leuven, Belgium
³Molecular Signaling and Cell Death Unit, Department for Molecular Biomedical Research, VIB, Ghent, Belgium
⁴Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium

Published: June 26, 2018

This article has been corrected: The correct Supplementary Figure S2C is given below. The authors' explanation is as follows:

Due to erroneous figure processing and oversight, unintended mistakes occurred during the assembly of Supplementary Figure S2C - specifically, the BiP/Grp78, CHOP and Actin panels for the AY27-PDT samples only. Using the source/raw data, we have now generated the correct Supplementary Figure S2C.

The authors apologize for the oversight. The authors declare that this correction does not affect the description, interpretation, or the original conclusions of the manuscript.

Original article: Oncotarget. 2015; 6:26841-26860. DOI: https://doi.org/10.18632/oncotarget.4754.

Supplementary Figure S2: Rat bladder carcinoma AY27 cells were treated or not (i.e. untreated controls/CNTR) with Hypericin-based Photodynamic Therapy (Hyp-PDT; 150 nM Hyp incubated for 16 h followed by irradiation with light fluence of 2.70 J/cm2) or mitoxantrone (MTX; 1 μM). C. immunoblotting for other ER stress markers like upregulation of BiP/GRP78 or CHOP levels at indicated recovery time-points. The calculations based on band densitometry analysis are mentioned as applicable.